|
|
Case Report Traditional Chinese Medicine Induced DRESS Syndrome: A Case Report and Literature Review SH Lau, JSC Wong, NC Fong, MYW Kwan Abstract Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially life-threatening drug related condition. Anti-epileptic agents and antibiotics are the most common culprit drugs. Delayed presentation and wide variety of clinical presentation make DRESS a diagnostic challenge. We reported a case of DRESS induced by Traditional Chinese Medicine. A detailed drug history with a high index of suspicion remains the key to early diagnosis. Keyword : DRESS syndrome; Hepatic dysfunction; Pleural effusion; Traditional Chinese Medicine IntroductionDrug reaction with eosinophilia and systemic symptoms (DRESS) was first described as a life-threatening drug-related clinical syndrome with multi-organ involvement by Saltzstein in 1959, and its name was later defined by Bocquet et al in 1996.1 Diagnosis of this entity is made by the Registry of International Study Group Investigating Severe Cutaneous Reactions (RegiSCAR) scoring system.2 Other Diagnostic criteria, such as the Japanese Consensus Group Severe Cutaneous Adverse Reactions (J-SCAR) highlighted the importance HHV-6 reactivation and delayed timing of onset of the DRESS clinical features. Among all the internal organ involvement, hepatic dysfunction (either hepatomegaly and/or elevated liver enzymes) was the most common, which was described in up to 94% of all cases. Lung involvement can be present in up to 50% of patients.3,4 Severe cases may result in intensive care unit admission and necessitate emergency liver transplantation in patients who develop fulminant liver failure.5 Mortality ranges from 3% to 10%.5-7 Relapsing disease has been reported to result in long-term autoimmune sequelae and other significant morbidities.8,9 Anti-epileptic agents were the most commonly reported culprit drug in the paediatric population, followed by sulphonamide antibiotics.7 Treatment options include immediate discontinuation of the incriminated drug and systemic corticosteroid therapy. Local paediatric studies are lacking due to the disease rarity. Local case series of DRESS with carbamazepine/co-trimoxazole use has been reported in Hong Kong.10 This case report serves to describe our positive treatment experience with add-on intravenous immunoglobulin combined with corticosteroid in a severe paediatric DRESS caused by Traditional Chinese Medicine. Case HistoryA 16-year-old boy was initially admitted for fever and abdominal pain. Computer tomography of the abdomen showed right duplex kidney with gross hydronephrosis and hydroureter. He was treated as urosepsis with intravenous antibiotics and percutaneous nephrostomy. Subsequently, he was noted to have raised transaminases and mild hyperbilirubinemia. Examination revealed mild hepatomegaly, bilateral cervical lymphadenopathy and faint erythematous maculopapular rash on the abdomen. The rash progressed in the next few days and became morbilliform with coalescence involving his trunk and limbs (Figure 1a). Nikolsy' sign was negative and there was no other mucosal involvement. Concurrently, he developed respiratory distress and Chest X-ray showed bilateral pleural effusion (Figure 1b), and he was transferred to paediatric intensive care unit for non-invasive respiratory support. Alanine aminotransferase (ALT) gradually rose to 3348 U/L on Day 9 with evidence of hepatic dysfunction (bilirubin 82 umol/L, albumin 23 g/L and pro-thrombin time 18 seconds, and International Normalised Ratio 1.7). Complete blood count showed thrombocytopenia (Platelets 83 x 109/L), mild leukocytosis (White blood cell 11.2 x 109/L), serum eosinophilia 1.3 x 109/L (12.7%) and presence of atypical lymphocytes (6%). C-reactive protein was 18 mg/L. Human Herpesvirus 6 (HHV-6) DNA was detected in serum nucleic acid testing. Other infection screening including blood culture, nephrostomy urine culture, nasopharyngeal swab for common respiratory viruses and bacteria (Streptococcus pneumoniae, Mycoplasma pneumoniae, Legionella) were negative. Serological tests for Hepatitis A, B, C and E, Epstein–Barr virus, cytomegalovirus and human immunodeficiency virus were negative. Other autoimmune and metabolic workup for hepatitis including serum ceruloplasmin, anti-smooth muscle antibody, anti-liver-kidney-microsomes antibody were unremarkable. Serum paracetamol level was below toxicity level <34 umol/L. He has been in good health until he had his first episode of generalised tonic-clonic convulsion 14 months ago. Computer Tomography of the brain showed no structural abnormalities but one episode of burst of spike and wave discharge was noted over his left frontal and occipital region on electroencephalogram. He was offered a drug-free observation in our neurology clinic for his first afebrile convulsion but subsequently he had defaulted follow up. His seizure recurred three times with similar semiology and he was prescribed with multiple unlabelled Traditional Chinese Medicine powder and multiple vitamin sup-plement tablets in twice daily dosing by a local Chinese practitioner 5 weeks prior to his symptom's onset. He also had a transient faint rash on his abdomen after applying self-purchased over-the-counter massage oil "Huo Luo You" for abdominal pain. There was in-significant travel history and contact history. He received full vaccination for Hepatitis B and there was no family history of chronic hepatitis. A diagnosis of DRESS was made clinically in view of recent drug use, serum eosinophilia with the presence of atypical lymphocytes, presence of characteristic skin rash and systemic symptoms (haematological, hepatic and pulmonary involvement). The diagnosis was also supported by the Registry of Severe Cutaneous Adverse Reaction (RegiSCAR) scoring system, in which the patient scored 8 out of 9 (Table 1). Systemic screening including echocardiogram, renal function and thyroid function tests were normal. All ten items of the unlabelled Traditional Chinese Medicine powder and the vitamin tablets were sent to the Toxicology Reference Laboratory. The unlabelled powder was later identified to be containing phenytoin and phenobarbital. Phenobarbital was detected in the patient's urine toxicology analysis. The offending agents were removed immediately after admission. He was treated with intravenous methylprednisolone 500 mg for 3 days. In view of severe multi-organ involvement and rising ALT despite methylprednisolone, intravenous immunoglobulin (IVIg) 2 gram/kg divided in 4 days was also given. He became afebrile within 48 hours after steroid administration. ALT gradually improved (Figure 2) and was normalised after one month. His coagulopathy was corrected by intravenous vitamin K and fresh frozen plasma. His ventilation was supported by Bi-level Positive Airway Pressure with maximal inspiratory positive airway pressure of 20 cmH2O. PaO2/FiO2 ratio was all along normal and oxygen therapy was successfully weaned off on Day 12. The pleural effusion resolved with conservative treatment. His rash gradually subsided with residual hyperpigmentation. Oral prednisolone was given after pulse methylprednisolone, which will be tapered in 2 months. He was discharged on Day 21 and had his follow-up appointments in neurology, immunology and dermatology subspecialty clinics. His seizure was controlled with levetiracetam.
DiscussionGreat Mimicker Prolonged Recovery and HHV-6 Positive Experience with Add-on IVIg Therapy Although early administration of pulsed intravenous methylprednisolone was associated with good clinical outcome in a prospective study,13 the benefit on acute liver failure is unproven.5 In view of persistently elevated transaminases with coagulopathy and multi-organ involvement, IVIg was administered as an add-on therapy. Both adult and paediatric studies have suggested potential benefits of IVIg for steroid hyposensitive DRESS.14,15 In our patient, ALT level showed prompt improvement within 48 hours after IVIg (Figure 2). Side effects including facial flushing, malaise, haemodynamic disturbances, pulmonary embolism have been reported in the literature16 but none of these were found in our patient.
Concerning other treatment options, other immunosuppressive agents and anti-viral therapy for HHV-6 were not considered in our patient as he demonstrated good response to steroid and IVIg. Combined N-acetylcysteine with corticosteroid use for DRESS has been described with favourable outcome in case reports due to initial suspicion of paracetamol toxicity.17,18 However, there were no randomised controlled studies to provide conclusive evidence on its efficacy in non-paracetamol-induced acute liver failure.19 Tofacitinib, a novel therapeutic agent targeting the JAK-STAT-dependent cytokines pathway has been described in 2020.20 Prognosis ConclusionDelayed presentation and wide variety of clinical presentation make DRESS a diagnostic challenge. A meticulously taken drug history with a high index of suspicion remains the key to the diagnosis of this life-threatening condition. Physicians should be alerted to the possible triggering ingredients in Traditional Chinese Medicine. Early diagnosis and prompt treatment are essential for a better patient outcome. Conflict of InterestThe authors have no conflicts of interest to disclose. References1. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensi-tivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7. 2. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-80. 3. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97. 4. Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I. Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review. Biomed Res Int 2019;2019:7863815. 5. Ichai P, Laurent-Bellue A, Saliba F, et al. Acute Liver Failure/Injury Related to Drug Reac-tion With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors. Transplantation 2017;101:1830-7. 6. Metterle L, Hatch L, Seminario-Vidal L. Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature. Pediatr Dermatol 2020;37:124-9. 7. Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosino-philia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature. J Am Acad Dermatol 2020;83:1323-30. 8. Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013;68:459-65. 9. Afiouni R, Zeinaty P, Kechichian E, et al. Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature, with a focus on relapsing cases. Pediatr Dermatol 2021;38:125-31. 10. Chua GT, Rosa Duque JS, Chong PCY, Lee PPW, Lau YL, Ho MHK. Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. Eur Ann Allergy Clin Immunol 2018;50:273-6. 11. Szewc AM, Taylor S, Cage GD, Jacobsen J, Bulut OP, de Mello DE. Acute Liver Failure in an Adolescent Male Induced by Human Herpesvirus 6 (HHV-6): A Case Report With Literature Review. Lab Med 2018;49:165-74. 12. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reac-tivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934-40. 13. Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosin-ophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol 2011;21:385-91. 14. Sim DW, Yu J, Koh YI. Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome. Clin Transl Sci 2022;15:782-8. 15. Marcus N, Smuel K, Almog M, et al. Successful Intravenous Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome. J Allergy Clin Immunol Pract 2018;6:1238-42. 16. Joly P, Janela B, Tetart F, et al. Poor benefit/risk balance of intravenous immunoglobu-lins in DRESS. Arch Dermatol 2012;148:543-4. 17. Pérez-Reyes E, Casanova-Lara A, Pérez-Torres E, Córdova J. Reversal of acute liver fail-ure with N-acetylcysteine and prednisone in a patient with DRESS syndrome: a case re-port and literature review. Rev Gastroenterol Mex 2014;79:208-10. 18. Moling O, Tappeiner L, Piccin A, et al. Treatment of DIHS/DRESS syndrome with com-bined N-acetylcysteine, prednisone and valganciclovir -- a hypothesis. Med Sci Monit 2012;18:CS57-62. 19. Siu JT, Nguyen T, Turgeon RD. N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure. Cochrane Database Syst Rev 2020;12:CD012123. 20. Kim D, Kobayashi T, Voisin B, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med 2020;26:236-43. 21. Sachs B, Fatangare A, Sickmann A, Glässner A. Lymphocyte transformation test: History and current approaches. J Immunol Methods 2021:493:113036. |